BackZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Overview

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Total Current Liabilities

Track ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s total current liabilities ($15B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$14.87B
23.85% YoYΔ $2.86B vs prior year quarter

Peer average / median

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Total Current Liabilities History

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) vs. peers: Total Current Liabilities Comparison

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) (LSPRU) FAQ

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) posts a total current liabilities of $15B as of March 2026. That compares with $12B in the prior-year period — up 23.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s total current liabilities was $12B. The latest reading is $15B — a 23.9% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s financial statement story. At $15B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LSPRU's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s other metric pages and overview cover the third.